Detalhe da pesquisa
1.
A population pharmacokinetic-pharmacodynamic model of navtemadlin, its glucuronide metabolite (M1) and serum macrophage inhibitory cykokine-1 (MIC-1).
Xenobiotica
; 52(6): 555-566, 2022 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-36052821
2.
Estimating the Population Health Impact of Recently Introduced Modified Risk Tobacco Products: A Comparison of Different Approaches.
Nicotine Tob Res
; 23(3): 426-437, 2021 02 16.
Artigo
em Inglês
| MEDLINE | ID: mdl-32496514
3.
Population Modeling of Modified Risk Tobacco Products Accounting for Smoking Reduction and Gradual Transitions of Relative Risk.
Nicotine Tob Res
; 19(11): 1277-1283, 2017 Nov 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28371856
4.
Population pharmacokinetic analysis of axitinib in healthy volunteers.
Br J Clin Pharmacol
; 77(3): 480-92, 2014 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-23834452
5.
Phase 1 Concentration-QTc and Cardiac Safety Analysis of the MDM2 Antagonist KRT-232 in Patients With Advanced Solid Tumors, Multiple Myeloma, or Acute Myeloid Leukemia.
Clin Pharmacol Drug Dev
; 10(8): 918-926, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-33460527
6.
Population pharmacokinetic and exposure-response analyses of ivosidenib in patients with IDH1-mutant advanced hematologic malignancies.
Clin Transl Sci
; 14(3): 942-953, 2021 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-33493392
7.
Exposure-Response-Based Product Profile-Driven Clinical Utility Index for Ipatasertib Dose Selection in Prostate Cancer.
CPT Pharmacometrics Syst Pharmacol
; 8(4): 240-248, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30762302
8.
Axitinib in metastatic renal cell carcinoma: results of a pharmacokinetic and pharmacodynamic analysis.
J Clin Pharmacol
; 53(5): 491-504, 2013 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-23553560
9.
Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis.
Cancer Chemother Pharmacol
; 66(2): 357-71, 2010 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-19967539
10.
A pharmacokinetic-pharmacodynamic model to optimize the phase IIa development program of maraviroc.
J Acquir Immune Defic Syndr
; 42(2): 183-91, 2006 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-16639345
11.
Combining drug-disease and economic modelling to inform drug development decisions.
Drug Discov Today
; 6(22): 1165-1170, 2001 Nov 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-11700218